Q3 Earnings Estimate for CORT Issued By Zacks Research

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Zacks Research issued their Q3 2026 earnings per share estimates for Corcept Therapeutics in a research report issued on Wednesday, September 16th. Zacks Research analyst Team forecasts that the biotechnology company will post earnings of $0.65 per share for the quarter. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $2.02 per share. Zacks Research also issued estimates for Corcept Therapeutics’ FY2026 earnings at $1.39 EPS.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings data on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.34. Corcept Therapeutics had a return on equity of 8.26% and a net margin of 6.52%.The business had revenue of $256.15 million for the quarter, compared to analysts’ expectations of $221.15 million. During the same period in the prior year, the firm earned $0.29 EPS. The company’s revenue for the quarter was up 31.7% on a year-over-year basis.

CORT has been the topic of several other reports. HC Wainwright raised their target price on Corcept Therapeutics from $95.00 to $165.00 and gave the stock a “buy” rating in a report on Thursday, July 30th. Truist Financial started coverage on shares of Corcept Therapeutics in a research report on Tuesday, August 18th. They issued a “buy” rating and a $164.00 price objective on the stock. UBS Group set a $135.00 price objective on shares of Corcept Therapeutics in a research report on Thursday, May 28th. Weiss Ratings lowered Corcept Therapeutics from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday, September 8th. Finally, Piper Sandler reaffirmed an “overweight” rating and set a $165.00 price objective (up from $88.00) on shares of Corcept Therapeutics in a report on Thursday, July 30th. Five research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $138.17.

Corcept Therapeutics Stock Performance

Shares of NASDAQ:CORT opened at $114.86 on Friday. Corcept Therapeutics has a one year low of $28.66 and a one year high of $126.38. The firm has a market cap of $12.42 billion, a PE ratio of 273.48 and a beta of 0.45. The firm’s 50 day simple moving average is $108.19 and its 200-day simple moving average is $74.96.

Institutional Trading of Corcept Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in CORT. BlackRock Inc. purchased a new position in shares of Corcept Therapeutics in the 2nd quarter worth about $1,080,964,000. First Trust Advisors LP lifted its holdings in Corcept Therapeutics by 213.5% in the first quarter. First Trust Advisors LP now owns 2,173,376 shares of the biotechnology company’s stock worth $87,609,000 after buying an additional 1,480,059 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Corcept Therapeutics by 38.0% during the 4th quarter. Geode Capital Management LLC now owns 2,668,918 shares of the biotechnology company’s stock valued at $92,892,000 after buying an additional 734,646 shares in the last quarter. Norges Bank purchased a new stake in shares of Corcept Therapeutics in the 4th quarter worth approximately $24,213,000. Finally, Bank of New York Mellon Corp bought a new stake in Corcept Therapeutics during the 2nd quarter valued at about $49,185,000. 93.61% of the stock is currently owned by institutional investors.

Insider Activity

In related news, insider Roberto Vieira sold 58,333 shares of the company’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $110.76, for a total transaction of $6,460,963.08. Following the completion of the transaction, the insider directly owned 4,242 shares in the company, valued at $469,843.92. This represents a 93.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Kimberly Park sold 26,685 shares of the business’s stock in a transaction that occurred on Wednesday, August 26th. The stock was sold at an average price of $122.55, for a total value of $3,270,246.75. Following the transaction, the director owned 30,000 shares of the company’s stock, valued at approximately $3,676,500. This represents a 47.08% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 446,119 shares of company stock valued at $50,644,753 over the last three months. 20.70% of the stock is currently owned by company insiders.

More Corcept Therapeutics News

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Zacks raises longer-term EPS forecasts. Zacks Research increased its estimates for Q4 2026 EPS to $0.68 from $0.62, FY2027 EPS to $2.05 from $1.91, and FY2028 EPS to $4.31 from $4.07. The firm also lifted its Q3 2027 forecast to $0.78 from $0.66, signaling improving expectations for Corcept’s earnings trajectory. Corcept Therapeutics analyst estimates
• Positive Sentiment: Commercial momentum supports the growth outlook. Korlym sales increased 6.2% in the first half of 2026, while the launch of Lifyorli could diversify revenue beyond Corcept’s established Cushing’s syndrome treatment. The company’s latest reported quarter also showed revenue growth of 31.7% year over year and EPS well above consensus estimates. Zacks report on Korlym and Lifyorli
• Neutral Sentiment: Near-term estimates are mixed. Zacks projects Q3 2026 EPS of $0.65, while its FY2026 forecast of $1.39 is below the broader consensus estimate of $2.02. This disparity may create uncertainty around the timing of earnings growth, despite more optimistic forecasts for 2027 and 2028.
• Neutral Sentiment: Analyst sentiment remains broadly favorable. Corcept has a “Moderate Buy” consensus rating and an average price target of $138.17, with several firms maintaining or raising bullish targets. However, the stock trades at a very high earnings multiple, increasing its sensitivity to disappointments.
• Negative Sentiment: Insiders reported additional selling. Director James Wilson sold 10,000 shares for approximately $1.11 million, reducing his position by 0.93%. Joseph Lyon also sold 10,000 shares, cutting his holdings by 63.76%. Wilson still owns more than 1.06 million shares, which may temper—but does not eliminate—the negative signal from insider sales. Corcept Therapeutics insider selling report

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated is a biopharmaceutical company focused on discovering and developing medicines that modulate the effects of the stress hormone cortisol. The company’s research centers on the glucocorticoid receptor, which regulates cortisol activity and may play a role in metabolic, psychiatric, oncologic and other serious diseases.

Corcept’s commercial product is Korlym (mifepristone), an oral glucocorticoid receptor antagonist approved in the United States to control hyperglycemia secondary to endogenous Cushing’s syndrome in adults with type 2 diabetes or glucose intolerance who are not candidates for surgery or have not responded adequately to surgery.